KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Other Operating Expenses (2016 - 2017)

Pfizer (PFE) has disclosed Other Operating Expenses for 8 consecutive years, with -$5.6 billion as the latest value for Q4 2017.

  • On a quarterly basis, Other Operating Expenses rose 4.69% to -$5.6 billion in Q4 2017 year-over-year; TTM through Jul 2018 was -$5.6 billion, a 65.32% increase, with the full-year FY2015 number at -$24.0 billion, down 4.48% from a year prior.
  • Other Operating Expenses was -$5.6 billion for Q4 2017 at Pfizer, down from -$5.2 billion in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.1 billion in Q2 2013 to a low of -$8.1 billion in Q4 2015.
  • A 5-year average of -$3.5 billion and a median of -$5.2 billion in 2015 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 261.14% in 2013, then crashed 9935.85% in 2015.
  • Pfizer's Other Operating Expenses stood at $18.0 million in 2013, then surged by 194.44% to $53.0 million in 2014, then crashed by 15349.06% to -$8.1 billion in 2015, then increased by 27.2% to -$5.9 billion in 2016, then rose by 4.69% to -$5.6 billion in 2017.
  • Per Business Quant, the three most recent readings for PFE's Other Operating Expenses are -$5.6 billion (Q4 2017), -$5.2 billion (Q3 2017), and -$5.1 billion (Q2 2017).